The observations that more aggressive breast and prostate cancer cell lines express higher levels of PRSS2 than their less metastatic counterparts coupled with the corroboration of these findings in patient samples, led us to hypothesize that disrupting PRSS2 expression could inhibit tumor growth. This evidence concerns the gene PRSS2 and prostate cancer.